Intricon CORP Stock: price and directors' dealings · United States · SEC (Form 4)Follow the Intricon CORP share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Intricon CORP has published 41 public disclosures. The latest transaction was disclosed on 25 May 2022 (Attribution). Among the most active insiders: Longval Scott. Every trade is openly available.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 25 May 2022
All Executives41 Thresholds0 Prospectus0 Other0
Declarations 41 total
◆ VP Sales & Marketing · Executives · 24 May 2022
4,021 shares 0Common Stock SEC:0000897101-22-000557:0
● Director · Executives · 24 May 2022
3,586 shares Common Stock SEC:0000897101-22-000558:0
● Director · Executives · 18 May 2022
4,000 shares 0Common Stock SEC:0000897101-22-000563:0
● Director · Executives · 24 May 2022
265,616 shares Common Stock SEC:0000897101-22-000562:0
● Director · Executives · 24 May 2022
11,154 shares Common Stock SEC:0000897101-22-000560:0
● Director · Executives · 24 May 2022
12,203 shares Common Stock SEC:0000897101-22-000561:0
● Director · Executives · 24 May 2022
9,121 shares Common Stock SEC:0000897101-22-000559:0
● President, CEO · Executives · 24 May 2022
2,000 shares 0Common Stock SEC:0000897101-22-000554:0
◆ Interim CFO · Executives · 24 May 2022
2,271 shares 0Common Stock SEC:0000897101-22-000555:0
◆ Vice President, Operations · Executives · 24 May 2022
6,885 shares 0Common Stock SEC:0000897101-22-000556:0
◇ VP Sales & Marketing · Executives · 12 May 2022
8,000 shares @ US$6.90 22.9% of flow Common Stock SEC:0000897101-22-000515:0
● President, CEO · Executives · 1 May 2022
610 shares @ US$24.01 2.6% of flow Common Stock SEC:0000897101-22-000500:0
● Vice President, Operations · Executives · 1 May 2022
610 shares @ US$24.01 5.7% of flow Common Stock SEC:0000897101-22-000501:0
● VP Sales & Marketing · Executives · 1 May 2022
610 shares @ US$24.01 6.0% of flow Common Stock SEC:0000897101-22-000502:0
● President, CEO · Executives · 12 Mar 2022
78 shares @ US$23.75 0.3% of flow Common Stock SEC:0000897101-22-000236:0
● VP Sales & Marketing · Executives · 12 Mar 2022
56 shares @ US$23.75 0.5% of flow Common Stock SEC:0000897101-22-000235:0
● Vice President, Operations · Executives · 12 Mar 2022
52 shares @ US$23.75 0.5% of flow Common Stock SEC:0000897101-22-000237:0
◆ VP Sales & Marketing · Executives · 15 Feb 2022
4,789 shares @ US$16.51 30.1% of flow Common Stock SEC:0000897101-22-000141:0
◆ Interim CFO · Executives · 15 Feb 2022
3,786 shares @ US$16.51 95.3% of flow Common Stock SEC:0000897101-22-000140:0
◆ Vice President, Operations · Executives · 15 Feb 2022
9,180 shares @ US$16.51 55.1% of flow Common Stock SEC:0000897101-22-000142:0
◆ President, CEO · Executives · 15 Feb 2022
26,953 shares @ US$16.51 72.9% of flow Common Stock SEC:0000897101-22-000139:0
● Interim CFO · Executives · 12 Feb 2022
117 shares @ US$16.82 3.0% of flow Common Stock SEC:0000897101-22-000132:0
● President, CEO · Executives · 12 Feb 2022
683 shares @ US$16.82 1.9% of flow Common Stock SEC:0000897101-22-000133:0
● Director · Executives · 10 Dec 2021
2,000 shares 0Common Stock SEC:0000897101-22-000040:0
● Interim CFO · Executives · 5 Jan 2022
72 shares @ US$15.55 1.7% of flow Common Stock SEC:0000897101-22-000027:0
25 of 41 declarations
Load more (16 remaining) 关于 Intricon CORP IntriCon Corp.(股票代码 IIN)是在美国 NASDAQ 上市交易的美国上市公司,专注于微医疗设备和微型组件的设计和制造。该公司的历史可以追溯到 1930 年,当时在宾夕法尼亚州成立,而其现代业务是围绕可穿戴身体技术和互联健康应用而建立的。公司总部位于明尼苏达州阿登山,在北美、欧洲和亚洲拥有国际业务足迹。对于法语使用者投资者而言,IntriCon 属于医疗保健工业领域:是 B2B 技术供应商,而非面向消费者的医疗品牌。
IntriCon 的核心业务是通过共同开发、工业化和生产超小型、高精度组件和设备,为医疗设备制造商和专业通信客户提供支持。该公司设计、工程设计、制造和分销微型产品、微电子和微机械子组件,以及完整的设备解决方案,服务于听力保健、医疗生物遥测和专业音频通信等增长市场。这使得 IntriCon 更像是一个技术合作伙伴而非纯粹的代工制造商,价值创造集中在微型化、系统集成和精密制造上。
从竞争角度来看,IntriCon 在技术专业知识、产品认证、长期客户关系和制造纪律比单纯规模更重要的市场中运营。其商业模式受益于共同工程能力、复杂的制造流程,以及为需要可靠性、可重复性和更快上市时间的原始设备制造商客户服务的能力。关键产品和服务包括微机械组件、电子组件、可穿戴设备和为医疗和通信合作伙伴提供的集成制造解决方案。
从地理位置来看,该公司的多地点业务足迹具有战略重要性。它通过美国和海外的设施运营,能够支持全球客户群并使其生产链的部分多样化。一个值得注意的最近发展是 2025 年 1 月宣布的阿登山总部扩建,旨在增加生产能力,这表明需求持续存在和运营投资。总体而言,IntriCon 仍然是一家专业的医疗保健工业公司:规模相对较小,但暴露于结构性吸引力强的终端市场,具有利基地位,可能对寻求在美国 NASDAQ 上获得医疗设备供应链敞口的投资者感兴趣。